F98604

F98604 is a hemisynthetic dimethylaminomethyl benzamide derivative of the Amaryllidaceae alkaloid narciclasine, developed by Pierre Fabre. It was designed as part of a chemistry program to improve the physicochemical and pharmacological properties of natural isocarbostiryl alkaloids like pancratistatin and narciclasine, which are often limited by poor water solubility and systemic toxicity. F98604 demonstrates potent antiproliferative activity, particularly against melanoma, by inhibiting DNA synthesis and inducing mitochondrial depolarization and pro-apoptotic signaling. Preclinical studies in murine B16 and human A375 melanoma xenograft models have shown that F98604 possesses a significantly improved therapeutic index compared to its parent compound, narciclasine.

Other names

dimethylaminomethyl benzamide derivative of narciclasine1-aminopancratistatin derivative